Compare Sanofi SA (SNY) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Tripadvisor Inc Common Stock — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Tripadvisor Inc Common Stock trades at $8.68 (market cap $1.01B). The key difference: Sanofi SA is far larger — about 94.2× Tripadvisor Inc Common Stock's market cap, and Sanofi SA pays a 6.01% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| SNY | TRIP | |
|---|---|---|
Market Cap | $95.18B | $1.01B |
Volume | 2,995,646 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $16.72 |
52-Week Low | $39.51 | $8.04 |
Typical Hold Time | 94 Days | 57 Days |
Enterprise Value | $114.48B | $1.06B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
TripAdvisor (TRIP) trades at $8.96, up 3.82% today but near 52-week lows, with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported Q2 2026 earnings of $0.35 per share, missing estimates, while revenue trends show modest growth from $1.5B in 2022 to $1.9B in 2025. Analyst consensus is mixed with 62.5% hold ratings and a $13.58 price target, representing 52% upside potential from current levels.
The investment case hinges on TripAdvisor's ability to stabilize its core business amid AI disruption in travel planning. While valuation appears reasonable with P/S of 0.57 and EV/EBITDA of 6.28, recent earnings misses and competitive pressures from AI platforms create significant headwinds. The stock offers substantial upside if management can execute on growth initiatives, but faces execution risk in a rapidly evolving travel technology landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
